Dr. Richard Carvajal, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Memorial Sloan Kettering

  Fellowship Hospital, 2007

• University Of Michigan Hospitals

  Residency Hospital, 2003

• New York University Grossman School Of Medicine

  Medical School, 2000

• The reporting of uveal melanoma cases to the cancer registry in North Carolina, 2022-08-03

• Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial, 2022-10-13

• Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma, 2012-08-05

• Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma, 2019-07-11

• Multi-modal single-cell and whole-genome sequencing of small, frozen clinical specimens, 2023-01-09

• A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors, 2014-11-14

• A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Ka Inhibitor, in Patients with Metastatic Uveal Melanoma, 2021-11-02

• Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center and University Hospital of Lausanne experience, 2013-08-02

• Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies, 2022-02-25

• Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205, 2014-04-16

• Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials, 2015-02-17

• Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment (TIME) and identifies a combination biomarker for primary melanoma, 2020-01-16

• Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion and MEK-resistance., 2012-05-01

• Effect of Selumetinib versus Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial, 2014-06-18

• Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition, 2015-02-18

• Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy, 2022-08-29

• Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, 2012-06-02

• Intermittent MEK inhibition for the treatment of metastatic uveal melanoma, 2022-09-29

• Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy), 2022-09-04

• Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens forBRAF-Mutant Melanoma, 2019-10-24

• Ipilimumab in patients with melanoma and autoimmune disease, 2014-10-14

• Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence, 2021-12-20

• Advances in Prevention and Surveillance of Cutaneous Malignancies, 2019-11-09

• A Phase 2 Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI#6366), 2009-05-19

• Comparing RECIST 1.1 and iRECIST in Advanced Melanoma Patients Treated with pembrolizumab in a Phase II Clinical Trial, 2020-09-30

• MicroRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortality, 2020-01-25

• Single institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after two doses correlates with survival, 2010-04-01

• MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma, 2021-01-15

• Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K- mutated melanoma, 2013-02-26

• A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol, 2010-02-21

• Prevalence of tumor infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment, 2014-11-15

• Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe, 2014-10-29